
Aldeyra Therapeutics, Inc.: updates and filings
Price
$0.84
November 20, 2026Market cap $51M
What Ploutos Investor adds for Aldeyra Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2013
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 36% since Nov 5, 2026, when the 10-Q these figures come from was filed ($0.62 then, $0.84 on Nov 20, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 17, 2026Delisting noticeForm8-K
- Nov 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 9, 2026Other material eventsForm8-K
- Nov 6, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Sep 29, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 30, 2026Material agreement enteredForm8-K
- Jul 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 15, 2026Other material eventsForm8-K
- Jun 10, 2026Officer or director change, shareholder vote, Regulation FD disclosureForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 1, 2026Regulation FD disclosureForm8-K
- Apr 27, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 27, 2026Additional annual meeting materialFormDEFA14A
- Apr 27, 2026Annual meeting proxy statementFormDEF 14A
- Apr 20, 2026Officer or director changeForm8-K
- Apr 1, 2026Other material eventsForm8-K
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 17, 2026Regulation FD disclosure, other material eventsForm8-K
- Feb 27, 2026Shares registered for employeesFormS-8
- Feb 27, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 17, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 17, 2026 | 8-K | Delisting notice | Document |
| Nov 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 9, 2026 | 8-K | Other material events | Document |
| Nov 6, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Sep 29, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 30, 2026 | 8-K | Material agreement entered | Document |
| Jul 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 15, 2026 | 8-K | Other material events | Document |
| Jun 10, 2026 | 8-K | Officer or director change, shareholder vote, Regulation FD disclosure | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 1, 2026 | 8-K | Regulation FD disclosure | Document |
| Apr 27, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 27, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 27, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 20, 2026 | 8-K | Officer or director change | Document |
| Apr 1, 2026 | 8-K | Other material events | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 17, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Feb 27, 2026 | S-8 | Shares registered for employees | Document |
| Feb 27, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 17, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Oct 6, 2005.
The full analysis
What do Aldeyra Therapeutics's filings show?
The filings are where every one of Aldeyra Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.